{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T21:06:02Z","timestamp":1772053562778,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.pupt.2024.102328","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T21:33:09Z","timestamp":1726608789000},"page":"102328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Elexacaftor\/tezacaftor\/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7222-0094","authenticated-orcid":false,"given":"E.","family":"Fragoso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Boaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gamboa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.M.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Carreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.S.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10290","key":"10.1016\/j.pupt.2024.102328_bib1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"issue":"10059","key":"10.1016\/j.pupt.2024.102328_bib2","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.pupt.2024.102328_bib3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic fibrosis. Taichman DB","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pupt.2024.102328_bib4","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1001\/archpedi.1938.01980140114013","article-title":"Cystic fibrosis of the pancreas and its relation to celiac disease: a clinical and pathologic study","volume":"56","author":"Andersen","year":"1938","journal-title":"Am. J. Dis. Child."},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2024.102328_bib6","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pupt.2024.102328_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2024.102328_bib8","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","author":"Ramsey","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pupt.2024.102328_bib9","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.pupt.2024.102328_bib11","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10212","key":"10.1016\/j.pupt.2024.102328_bib13","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pupt.2024.102328_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jcf.2023.02.004","article-title":"Elexacaftor\/tezacaftor\/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del","volume":"22","author":"Lopez","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"19","key":"10.1016\/j.pupt.2024.102328_bib15","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pupt.2024.102328_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"4","key":"10.1016\/j.pupt.2024.102328_bib17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","article-title":"Improved glucose tolerance after initiation of Elexacaftor\/Tezacaftor\/Ivacaftor in adults with cystic fibrosis","volume":"22","author":"Steinack","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2024.102328_bib18","author":"Sutharsan","year":"2023","journal-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry [Internet]"},{"key":"10.1016\/j.pupt.2024.102328_bib19","series-title":"24-week Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in People with Cystic Fibrosis Homozygous for F508del-CFTR: a Phase 3b Randomised Controlled Trial","author":"Sutharsan","year":"2021"},{"issue":"6","key":"10.1016\/j.pupt.2024.102328_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MCP.0000000000001014","article-title":"Neuropsychiatric adverse effects from CFTR modulators deserve a serious research effort","volume":"29","author":"VanElzakker","year":"2023","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.pupt.2024.102328_bib21","doi-asserted-by":"crossref","DOI":"10.36416\/1806-3756\/e20220312","article-title":"Elexacaftor\/tezacaftor\/ivacaftor\u2014real-world clinical effectiveness and safety. A single-center Portuguese study","author":"Lopes","year":"2023","journal-title":"J. Bras. Pneumol."},{"issue":"5","key":"10.1016\/j.pupt.2024.102328_bib22","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.pupt.2024.102328_bib23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.pupt.2024.102328_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01253-2023","article-title":"Cystic fibrosis and the cardiovascular system: the unexpected heartache","volume":"62","author":"Hebestreit","year":"2023","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.pupt.2024.102328_bib25","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.jcf.2021.01.011","article-title":"Measuring the impact of CFTR modulation on sweat chloride in cystic fibrosis: rationale and design of the chec-sc study","volume":"20","author":"Zemanick","year":"2021","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcf.2022.07.008","article-title":"Characterizing CFTR modulated sweat chloride response across the cf population: initial results from the CHEC-SC study","volume":"22","author":"Mayer-Hamblett","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.pupt.2024.102328_bib27","series-title":"D12 EPIDEMIOLOGY and THERAPY IN CF and NON-CF BRONCHIECTASIS [Internet]","article-title":"Promising results with elexacaftor\/tezacaftor\/ivacaftor use in cystic fibrosis patients with advanced lung disease: beyond the clinical trial inclusion criteria","author":"Bowen","year":"2020"},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib28","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/jcm10010023","article-title":"Real-world safety of CFTR modulators in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Dagenais","year":"2020","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.pupt.2024.102328_bib29","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/ppul.26412","article-title":"Management of neuropsychiatric symptoms in adults treated with elexacaftor\/tezacaftor\/ivacaftor","volume":"58","author":"Baroud","year":"2023","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.pupt.2024.102328_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jcf.2021.10.002","article-title":"Mental status changes during elexacaftor\/tezacaftor\/ivacaftor therapy","volume":"21","author":"Heo","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10.1016\/j.pupt.2024.102328_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jcf.2022.05.001","article-title":"Dose adjustments of Elexacaftor\/Tezacaftor\/Ivacaftor in response to mental health side effects in adults with cystic fibrosis","volume":"21","author":"Spoletini","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"12","key":"10.1016\/j.pupt.2024.102328_bib32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/thoraxjnl-2014-205983","article-title":"Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of the International Depression Epidemiological Study across nine countries","volume":"69","author":"Quittner","year":"2014","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.pupt.2024.102328_bib33","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1369\/jhc.2009.953455","article-title":"Expression and distribution of cystic fibrosis transmembrane conductance regulator in neurons of the human brain","volume":"57","author":"Guo","year":"2009","journal-title":"J. Histochem. Cytochem."},{"issue":"5","key":"10.1016\/j.pupt.2024.102328_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00381-003-0878-y","article-title":"History, anatomic forms, and pathogenesis of Chiari I malformations","volume":"20","author":"Schijman","year":"2004","journal-title":"Childs Nerv Syst."},{"issue":"4","key":"10.1016\/j.pupt.2024.102328_bib35","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3340\/jkns.2010.48.4.375","article-title":"Chiari 1.5 malformation : an advanced form of Chiari I malformation","volume":"48","author":"Kim","year":"2010","journal-title":"J Korean Neurosurg Soc"},{"issue":"3","key":"10.1016\/j.pupt.2024.102328_bib36","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.jcf.2022.01.010","article-title":"Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor\/Tezacaftor\/Ivacaftor initiation in a preadolescent with cystic fibrosis","volume":"21","author":"Wisniewski","year":"2022","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib37","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1164\/rccm.202303-0380LE","article-title":"Raised intracranial pressure in three children with cystic fibrosis receiving elexacaftor-tezacaftor-ivacaftor modulator therapy","volume":"208","author":"Southern","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1164\/rccm.202301-0021OC","article-title":"Long-Term Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged \u2a7e6 Years with Cystic Fibrosis and at Least One F508del Allele: A Phase 3, Open-Label Clinical Trial","volume":"208","author":"Wainwright","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.pupt.2024.102328_bib39","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.jcjo.2021.04.018","article-title":"Papilledema and hypervitaminosis A after elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis","volume":"57","author":"Miller","year":"2022","journal-title":"Can. J. Ophthalmol."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553924000440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553924000440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:29:02Z","timestamp":1733866142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553924000440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":39,"alternative-id":["S1094553924000440"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102328","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor\/tezacaftor\/ivacaftor, a game-changer in cystic fibrosis: The Portuguese experience","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2024.102328","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102328"}}